Teva Canada Limited / Teva Canada Limitee
Registration:
19
of
36
(2017-12-01
to
2018-02-13)
Policies or Program
- An opportunity for a multi-stakeholder approach in developing a solution for childhood diarrhea in low to middle income countries.
- Health Canada regarding the development and implementation of an approval pathway for Subsequent Entry Biologics (SEBs), Biologics and Specialty Products.
- Health Canada regarding the modernization of the Food and Drug Act (formerly Bill C-51) with respect to the development and implementation of a Progressive Licensing Framework for pharmaceuticals
- Health Canada's consultation on pain medicines.
- Innovation, Science and Economic Development Canada. Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.
- International Trade regarding intellectual property provisions in bilateral and multilateral trade agreements.
Regulation
- Innovation, Science and Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.